This tool is intended for educational purposes only and does not replace clinical judgment. Final treatment decisions should be made by the multidisciplinary treatment team.
# Specifically Immuno-Oncology (IO), targeted therapies & Antibody-Drug Conjugates (ADCs)).
This tool was last updated in January 2026, based on the latest reimbursement criteria from RIZIV/INAMI and may not be exhaustive.
For full reimbursement criteria, consult the FAGG website (https://www.fagg-afmps.be/nl).
Please consult ESMO guidelines for additional information: Zer A et al. Ann Oncol 2025;36(11):1245-1262, Hendriks LE et al. Ann Oncol 2023;34(4):358-376, Hendriks LE et al. Ann Oncol 2023;34(4):339-357.
References
- SmPC IMFINZI® version 02-07-2025, consulted in December 2025.
- SmPC TAGRISSO® version 06-11-2025, consulted in December 2025.
ADJ: adjuvant; ALK: anaplastic lymphoma kinase; CRT: chemoradiotherapy; CT: chemotherapy; EGFR: epidermal growth factor receptor; NSCLC: non-small cell lung cancer; PD-L1: programmed death-ligand 1; PERI: peri-operative (neo-adjuvant + adjuvant); SmPC: summary of product characteristics.
NS ID XL-5928-Revision Date 01/2026-LB Local code 178
